Brief: Innate Pharma Updates On SAR'579/IPH6101 In R/R Aml

Innate Pharma SA

26/05/2023 06:29

May 26 (Reuters) - Innate Pharma SA  IPH.PA :
    * INNATE PHARMA HIGHLIGHTS PHASE 1/2 DOSE ESCALATION SAFETY
AND
PRELIMINARY EFFICACY OF SANOFI DEVELOPED FIRST NK CELL ENGAGER
SAR’579 / IPH6101 IN R/R AML
    * PRELIMINARY DATA PUBLISHED SHOW SAR'579 WAS WELL TOLERATED
AND
INDUCED 3 COMPLETE RESPONSES IN 8 PATIENTS AT 1 MG/KG AS HIGHEST
DOSE
    * PHASE 1/2 DATA WILL BE PRESENTED AS AN ORAL PRESENTATION
AT ASCO
2023 ANNUAL MEETING
    * STUDY WILL NOW PROGRESS TO EXPANSION PHASE

Source text for Eikon:  ID:nBw1mj5zha 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))